Treatment Rankings

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / Treatment Rankings

📖

Treatment Rankings

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-rankings

📖 Wiki Page

therapeutic1869 wordssynced 2026-04-02

Treatment Rankings

Introduction

...

Treatment Rankings

Introduction

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Rankings</th>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Lecanemab](/entities/lecanemab)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Donanemab](/entities/donanemab)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Aducanumab</td>
</tr>
<tr>
<td class="label">4</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">5</td>
<td>Gosuranemab</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/entities/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Rivastigmine](/entities/rivastigmine)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Galantamine</td>
</tr>
<tr>
<td class="label">5</td>
<td>Namzaric</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levodopa/Carbidopa</td>
</tr>
<tr>
<td class="label">2</td>
<td>Pramipexole</td>
</tr>
<tr>
<td class="label">3</td>
<td>Rotigotine</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rasagiline</td>
</tr>
<tr>
<td class="label">5</td>
<td>Entacapone</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Deep Brain Stimulation</td>
</tr>
<tr>
<td class="label">2</td>
<td>Levodopa-carbidopa intestinal gel</td>
</tr>
<tr>
<td class="label">3</td>
<td>Apomorphine infusion</td>
</tr>
<tr>
<td class="label">4</td>
<td>Duodopa</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Relyvrio](/therapeutics/relyvrio-neurodegeneration) (Sodium Phenylbutyrate/Taurursodiol)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Edaravone](/therapeutics/amyotrophic-lateral-sclerosis-treatment)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Riluzole</td>
</tr>
<tr>
<td class="label">4</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">2</td>
<td>BIIB078</td>
</tr>
<tr>
<td class="label">3</td>
<td>ASO targeting [FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Non-invasive ventilation (NIV)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Percutaneous endoscopic gastrostomy (PEG) tube</td>
</tr>
<tr>
<td class="label">3</td>
<td>Speech therapy</td>
</tr>
<tr>
<td class="label">4</td>
<td>Physical therapy</td>
</tr>
<tr>
<td class="label">5</td>
<td>Occupational therapy</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Baclofen or Tizanidine</td>
</tr>
<tr>
<td class="label">2</td>
<td>Amitriptyline or Glycopyrrolate</td>
</tr>
<tr>
<td class="label">3</td>
<td>Quinine or Mexiletine</td>
</tr>
<tr>
<td class="label">4</td>
<td>SSRIs or SNRIs</td>
</tr>
<tr>
<td class="label">5</td>
<td>Lorazepam</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">HEALEY ALS Platform</td>
<td>Multiple arms</td>
</tr>
<tr>
<td class="label">CNTN4</td>
<td>CNversyt</td>
</tr>
<tr>
<td class="label">Masitinib</td>
<td>Masitinib</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">2</td>
<td>Trazodone</td>
</tr>
<tr>
<td class="label">3</td>
<td>Valproate</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levodopa/Carbidopa</td>
</tr>
<tr>
<td class="label">2</td>
<td>Amantadine</td>
</tr>
<tr>
<td class="label">3</td>
<td>Pramipexole</td>
</tr>
<tr>
<td class="label">4</td>
<td>Benztropine</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Prizm lenses</td>
</tr>
<tr>
<td class="label">2</td>
<td>Vision therapy</td>
</tr>
<tr>
<td class="label">3</td>
<td>Artificial tears</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>SSRIs (Sertraline, Escitalopram)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">3</td>
<td>Dextromethorphan/Quinidine</td>
</tr>
<tr>
<td class="label">4</td>
<td>Modafinil</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/entities/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Rivastigmine](/entities/rivastigmine)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">2</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">3</td>
<td>Tilavonemab</td>
</tr>
<tr>
<td class="label">4</td>
<td>AADvac1</td>
</tr>
<tr>
<td class="label">5</td>
<td>LTMX (Leurometaximel)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Physical therapy</td>
</tr>
<tr>
<td class="label">2</td>
<td>Occupational therapy</td>
</tr>
<tr>
<td class="label">3</td>
<td>Speech therapy (LSVT LOUD)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Swallowing therapy</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>Anti-tau antibody</td>
</tr>
<tr>
<td class="label">Eisoselenomethyl</td>
<td>Selenoprotein</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Multidisciplinary team</td>
</tr>
<tr>
<td class="label">2</td>
<td>Caregiver support</td>
</tr>
<tr>
<td class="label">3</td>
<td>Environmental modifications</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levodopa/Carbidopa</td>
</tr>
<tr>
<td class="label">2</td>
<td>Pramipexole</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">2</td>
<td>Benzodiazepines (Clonazepam)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Baclofen</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Levetiracetam</td>
</tr>
<tr>
<td class="label">2</td>
<td>Clonazepam</td>
</tr>
<tr>
<td class="label">3</td>
<td>Valproic acid</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/entities/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Rivastigmine](/entities/rivastigmine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">4</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">5</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">6</td>
<td>Quetiapine</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">2</td>
<td>Tilavonemab</td>
</tr>
<tr>
<td class="label">3</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Physical therapy</td>
</tr>
<tr>
<td class="label">2</td>
<td>Occupational therapy</td>
</tr>
<tr>
<td class="label">3</td>
<td>Speech therapy</td>
</tr>
<tr>
<td class="label">4</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">AAV gene therapy</td>
<td>Tau reduction</td>
</tr>
</table>

This page ranks therapeutic approaches and drugs for neurodegenerative diseases based on clinical evidence, FDA approval status, and therapeutic potential. [@cummings2024]

Alzheimer's Disease Treatments

Disease-Modifying Therapies (by evidence strength)

Symptomatic Treatments (by prescription frequency)

Parkinson's Disease Treatments

Motor Symptoms (by efficacy)

Advanced Therapies

Amyotrophic Lateral Sclerosis

Approved Disease-Modifying Treatments

Gene-Specific Therapies

Supportive Care (Essential for Quality of Life)

Symptomatic Management

Active Clinical Trials (Phase 3)

Emerging Approaches

Cell therapy: Stem cell transplantation (various trials)
Gene therapy: AAV-based delivery of protective genes
Combination therapy: Multi-target approaches in development
Biomarker-driven trials: Enrolling based on molecular subtypes

Frontotemporal Dementia

Symptomatic Approaches

Emerging Treatments (by development stage)

Phase 3

Amyloid immunotherapies: Continued development

Tau immunotherapies: Semorinemab, Zagotenemab

Phase 2

[Alpha-synuclein](/proteins/alpha-synuclein): Prasinezumab, Cinpanemab

Neuroprotective: Tyrosine kinase inhibitors

Anti-inflammatory: [NLRP3](/entities/nlrp3-inflammasome) inhibitors

Phase 1

Gene therapies: Various targets

Cell therapies: Stem cell approaches

Treatment Selection Criteria

When selecting treatments, consider:

Disease stage: Symptomatic vs. disease-modifying

Genetic factors: [APOE](/proteins/apoe) status, mutation carriers

Comorbidities: Cardiovascular, renal, hepatic

Patient preferences: Delivery method, side effects

Cost and access: Insurance, geographic availability

[Treatments Index](/therapeutics)
[Treatment Overview](/therapeutics/overview)
[Mechanisms](/mechanisms)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Progressive Supranuclear Palsy (PSP) Treatments

Symptomatic Pharmacological Treatments

Movement Symptoms (by efficacy)

Ocular Motor Dysfunction

Neuropsychiatric Symptoms

Cognitive Symptoms

Disease-Modifying Therapies (Tau-Targeting)

Non-Pharmacological Interventions

Emerging Therapies (Clinical Trials)

Supportive Care

Corticobasal Syndrome (CBS) Treatments

Motor Symptoms

Dopaminergic Agents

Dystonia and Spasticity

Myoclonus

Cognitive and Behavioral Symptoms

Disease-Modifying Therapies

Non-Pharmacological Interventions

Emerging Approaches

Coverage Gaps

Uncovered Disease Categories

The following neurodegenerative conditions lack dedicated treatment sections:

Multiple System Atrophy (MSA): No treatment rankings
Huntington's Disease: Only minimal mention in emerging treatments
Dementia with Lewy Bodies (DLB): No dedicated section
Vascular Dementia: No dedicated section

Underdeveloped Sections

Amyotrophic Lateral Sclerosis (ALS): Only 3 approved treatments listed - missing newer therapies (Relyvrio/Amylyx, dexpramipexole trials)
Frontotemporal Dementia: Only 3 symptomatic approaches - no disease-modifying therapies covered

Missing Treatment Categories

Disease-modifying therapies for PD: Only symptomatic and advanced therapies covered
Gene therapies: Only mentioned in Phase 1 - no dedicated ranking
Cell therapies: Only mentioned in Phase 1 - no dedicated ranking
Neuroprotective agents: Broad category but no dedicated section
Combination therapies: No ranking or analysis

Specific Missing Treatments

AD: Missing anti-amyloid beyond immunotherapies (e.g., bace inhibitors history)
PD: Missing newer dopamine agonists (e.g., noloparin)
ALS: Missing supportive care therapies (feeding tubes, ventilation)

References

[Cummings J, et al., Alzheimer's disease drug development pipeline. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13802)

[Fox NC, et al., Parkinson's disease therapies. Nat Rev Neurol. 2023 (2023)](https://doi.org/10.1038/s41582-023-00778-2)

[Colosimo et al., Lancet Neurology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32867888/)

[Höglinger et al., Lancet Neurology (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35613928/)

[Boxer et al., Neurology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32029420/)

[Litvan et al., Neurology (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29174120/)

[Stamelou et al., Mov Disord (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35680125/)

📖 View canonical wiki page →

Related Entities

RANKINGS

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-rankings
kg_node_id	RANKINGS
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-aecf35bd6149
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-rankings'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

Incoming

Outgoing

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (52)

mentions🧪Microbial Inflammasome Priming Prevention69%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna69%

mentions🧪Vagal Afferent Microbial Signal Modulation68%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy67%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones67%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer65%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides65%

mentions🧪Competitive APOE4 Domain Stabilization Peptides64%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction63%

mentions🧪Vocal Cord Neuroplasticity Stimulation63%

see_also📖Packard Center for ALS Research60%

see_also📖CBL Gene60%

see_also📖PIK3CA Gene60%

see_also📖RHOA Gene — Ras Homolog Family Member A60%

see_also📖TGFBR1 — TGF-beta Receptor 160%

see_also📖ACVR1 Gene60%

see_also📖PTEN Gene60%

see_also📖Aging vs Neurodegeneration: Mechanistic Comparison Matrix60%

see_also📖RAF1 — RAF1 Proto-Oncogene, Serine/Threonine Kinase (c-Raf)60%

see_also📖MAPK1 Gene60%

see_also📖PI3K — Phosphoinositide 3-Kinase60%

see_also📖RAC1 Gene60%

see_also📖CDC42 Gene60%

see_also📖MAPK Signaling Pathways in Neurodegeneration60%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧫GPR109A receptor validation using knockout macrophages44%

mentions🧫MAPK pathway inhibition by QTJD through butyrate mechanism44%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%

Reference URLs

Canonical (singular)/artifact/wiki-therapeutics-rankingscanonical

Canonical (plural, REST)/artifacts/wiki-therapeutics-rankingsalias

API (JSON)/api/artifacts/wiki-therapeutics-rankingsapi

Citation — BibTeX/artifacts/wiki-therapeutics-rankings/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-therapeutics-rankings/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-therapeutics-rankings/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-therapeutics-rankings?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Treatment Rankings](http://scidex.ai/artifact/wiki-therapeutics-rankings)

Direct URL

http://scidex.ai/artifact/wiki-therapeutics-rankings

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Treatment Rankings

Treatment Rankings

Introduction

Treatment Rankings

Introduction

Alzheimer's Disease Treatments

Disease-Modifying Therapies (by evidence strength)

Symptomatic Treatments (by prescription frequency)

Parkinson's Disease Treatments

Motor Symptoms (by efficacy)

Advanced Therapies

Amyotrophic Lateral Sclerosis

Approved Disease-Modifying Treatments

Gene-Specific Therapies

Supportive Care (Essential for Quality of Life)

Symptomatic Management

Active Clinical Trials (Phase 3)

Emerging Approaches

Frontotemporal Dementia

Symptomatic Approaches

Emerging Treatments (by development stage)

Phase 3

Phase 2

Phase 1

Treatment Selection Criteria

Related Pages

See Also

External Links

Progressive Supranuclear Palsy (PSP) Treatments

Symptomatic Pharmacological Treatments

Movement Symptoms (by efficacy)

Ocular Motor Dysfunction

Neuropsychiatric Symptoms

Cognitive Symptoms

Disease-Modifying Therapies (Tau-Targeting)

Non-Pharmacological Interventions

Emerging Therapies (Clinical Trials)

Supportive Care

Corticobasal Syndrome (CBS) Treatments

Motor Symptoms

Dopaminergic Agents

Dystonia and Spasticity

Myoclonus

Cognitive and Behavioral Symptoms

Disease-Modifying Therapies

Non-Pharmacological Interventions

Emerging Approaches

Coverage Gaps

Uncovered Disease Categories

Underdeveloped Sections

Missing Treatment Categories

Specific Missing Treatments

References

💬 Discussion